Last reviewed · How we verify
Prader-Willi syndrome
Approved treatments
- Pabal · Ferring Pharmaceuticals Ltd
- Duratocin · Dongyu Wang
- Omnitrope · Sandoz
- Omnitrope · Serono
Somatropin binds dimeric GH receptors on target cells, inducing intracellular signaling and GH-dependent protein synthesis including IGF-1. - somatropine · Sanofi
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Prader-Willi syndrome patent landscape — cliff calendar, originator estates, attackable patents
- Prader-Willi syndrome treatment landscape brief
- Prader-Willi syndrome treatment updates RSS
Frequently asked questions about Prader-Willi syndrome
What drugs treat Prader-Willi syndrome?
Tracked treatments include Pabal, Duratocin, Omnitrope, somatropine.
What is the treatment for Prader-Willi syndrome?
Standard treatment for Prader-Willi syndrome includes Pabal, Duratocin, Omnitrope, somatropine. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Prader-Willi syndrome patent cliff · Prader-Willi syndrome CI report
- Treatment: Pabal · Ferring Pharmaceuticals Ltd
- Treatment: Duratocin · Dongyu Wang
- Treatment: Omnitrope · Sandoz
- Treatment: Omnitrope · Serono
- Treatment: somatropine · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing